Durvalmab plus platinum-etoposide versus atezolizumab plus platinum-etoposide in extensive- stage small cell lung cancer: a systematic review.
Not Applicable
- Conditions
- extensive-stage (ES) small-cell lung cancer (SCLC) (ES-SCLC)
- Registration Number
- JPRN-UMIN000040194
- Lead Sponsor
- Showa University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 940
Inclusion Criteria
Not provided
Exclusion Criteria
Case report Observational studies non-randomized controlled trials
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival(OS)
- Secondary Outcome Measures
Name Time Method Progression free survival(PFS) Grade3-5 Any adverse events(G3-5AAEs) Grade3-5 neutropenia, anemia, thrombocytopenia